



REMARKS

Amendments

The specification has been amended to place the reference to the prior application as the first sentence of the specification and to replace the Sequence Listing. The new Sequence Listing is identical except for the addition of SEQ ID NOS:15-20. New SEQ ID NOS:15-20 are identical to SEQ ID NOS:2, 4, 6, 8, 10 & 12, respectively, of copending 08/971,172, which is the application cited on p.2, line 17 and p.4, line 29 as describing robo polypeptides.

In accordance with 37 CFR 1.821(e), we submit a computer readable form of the new Sequence Listing. The sequence information on the written Sequence Listing enclosed herewith is identical to that recorded in computer readable form. The foregoing amendments and submission introduce no new matter.

35USC112, first & second paragraph

The reference to "Slit" has been removed; the reference to "Robo" polypeptides has been replaced with reference to specific Robo polypeptides defined by SEQ ID NOS.

Double Patenting

Claim 27 has been corrected to depend on claim 10, differentiating it from claim 26.

Declaration pursuant to *In re Hawkins*, 179USPQ157, 163 & 167, see MPEP608.01(p)I.A.1.

By signing below, the undersigned hereby declares that the amendatory material consists of the same material incorporated by reference in this application.

The Examiner is invited to call the undersigned if he would like to amend the claims to clarify the foregoing or seeks further clarification of the claim language.

Applicants hereby petition for any necessary extension of time pursuant to 37 CFR 1.136(a). The Commissioner is hereby authorized to charge any fees or credit any overcharges relating to this communication to our Deposit Account No. 19-0750 (order no. B98-031-5).

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP

Richard Aron Osman, Ph.D., Reg. No. 36,627
Tel: (650) 343-4341; Fax: (650)343-4342

B